Table 1. Characteristics of patients in... | American Society of Hematology

Table 1.

Characteristics of patients in AML-HR trial by random assignment

	FLA vs ADE, no. patients			G-CSF vs no G-CSF, no. patients			ATRA vs no ATRA, no. patients
	FLA	ADE	G-CSF	None	ATRA	None
No. randomly assigned	126	124	178	178	180	182
Type of high risk
Adverse genetics	22	25	28	27	23	26
Not in CR at entry	5	13	15	10	13	8
In CR at entry	17	12	13	17	10	18
Resistant disease	41	38	64	61	65	64
Refractory disease	5	3	4	8	6	5
Relapse	58	58	82	82	86	87
CR1 less than 1 y	27	24	45	33	40	38
CR1 longer than 1 y	31	34	37	49	46	49
Age group
15-29 years of age	12	15	16	19	14	16
30-39 years of age	19	19	22	29	25	29
40-49 years of age	21	20	34	25	33	27
50-59 years of age	40	39	59	57	59	59
60-69 years of age	27	23	38	40	40	42
70 years of age or older	7	8	9	8	8	9
Sex
Female	61	62	82	91	90	83
Male	65	62	96	87	90	99
Type of AML
De novo	108	105	153	155	153	156
Secondary	18	19	25	23	27	20
Cytogenetic group
Favorable	7	3	4	10	8	7
Intermediate	45	44	66	65	66	68
Adverse	34	25	42	36	35	34
Unknown	40	52	66	67	71	73
Performance status
0	83	83	116	116	119	119
1	33	34	48	44	51	53
2	6	2	6	9	6	4
3	3	4	4	5	5	4
4	1	1	0	2	0	1
Prior transplantation	1	3	3	4	3	4
Randomizations
FLA	—	—	57	59	56	57
ADE	—	—	59	58	57	55
Not randomized	—	—	62	61	67	70
G-CSF	59	57	—	—	79	80
No G-CSF	58	59	—	—	80	80
Not randomized	9	8	—	—	21	22
ATRA	57	56	79	80	—	—
No ATRA	55	57	80	80	—	—
Not randomized	14	11	19	18	—	—

	FLA vs ADE, no. patients			G-CSF vs no G-CSF, no. patients			ATRA vs no ATRA, no. patients
	FLA	ADE	G-CSF	None	ATRA	None
No. randomly assigned	126	124	178	178	180	182
Type of high risk
Adverse genetics	22	25	28	27	23	26
Not in CR at entry	5	13	15	10	13	8
In CR at entry	17	12	13	17	10	18
Resistant disease	41	38	64	61	65	64
Refractory disease	5	3	4	8	6	5
Relapse	58	58	82	82	86	87
CR1 less than 1 y	27	24	45	33	40	38
CR1 longer than 1 y	31	34	37	49	46	49
Age group
15-29 years of age	12	15	16	19	14	16
30-39 years of age	19	19	22	29	25	29
40-49 years of age	21	20	34	25	33	27
50-59 years of age	40	39	59	57	59	59
60-69 years of age	27	23	38	40	40	42
70 years of age or older	7	8	9	8	8	9
Sex
Female	61	62	82	91	90	83
Male	65	62	96	87	90	99
Type of AML
De novo	108	105	153	155	153	156
Secondary	18	19	25	23	27	20
Cytogenetic group
Favorable	7	3	4	10	8	7
Intermediate	45	44	66	65	66	68
Adverse	34	25	42	36	35	34
Unknown	40	52	66	67	71	73
Performance status
0	83	83	116	116	119	119
1	33	34	48	44	51	53
2	6	2	6	9	6	4
3	3	4	4	5	5	4
4	1	1	0	2	0	1
Prior transplantation	1	3	3	4	3	4
Randomizations
FLA	—	—	57	59	56	57
ADE	—	—	59	58	57	55
Not randomized	—	—	62	61	67	70
G-CSF	59	57	—	—	79	80
No G-CSF	58	59	—	—	80	80
Not randomized	9	8	—	—	21	22
ATRA	57	56	79	80	—	—
No ATRA	55	57	80	80	—	—
Not randomized	14	11	19	18	—	—

— indicates not applicable.